Navigation Links
Brain tumor discovery could lead to new treatment
Date:7/8/2011

EMBARGOED UNTIL 12P.M. EST, Friday, July 8, 2011, Cleveland: Cleveland Clinic researchers have identified a cellular pathway that cancer stem cells use to promote tumor growth in malignant glioma, an aggressive brain tumor. The research published in the July 8 issue of Cell also found that existing medications block this cancer-promoting pathway and delay glioma growth in animal models, suggesting a new treatment option for these often fatal brain tumors.

Malignant gliomas account for more than half of the 35,000-plus primary malignant brain tumors diagnosed each year in the United States. Unfortunately, the outlook for patients with malignant gliomas is poor. For patients with the most severe, aggressive form of malignant glioma (grade IV glioma or glioblastoma multiforme), median survival is 9 to 15 months with the best available therapies. These treatments include surgery followed by radiation therapy with the chemotherapy temozolomide followed by additional temozolomide treatment.

Although differences in tumors between people were known to exist, researchers have only recently begun to understand the importance of differences between cancer cells within the same patient. Groups of cells within a glioma which promote brain tumor formation in animal models called cancer stem cells have been identified. These cancer stem cells are often resistant to radiation and chemotherapy, making them an important target for developing new and effective disease treatments.

In a recently published manuscript, a team of Cleveland Clinic researchers led by Jeremy Rich, M.D., Chairman, and Anita Hjelmeland, Ph.D., of the Department of Stem Cell Biology and Regenerative Medicine of the Lerner Research Institute of Cleveland Clinic define a novel molecular pathway that cancer stem cells use to promote tumor growth. Cancer stem cells produce elevated nitric oxide, a molecule whose role in cancer is not well defined but which has been linked to therapeutic resistance, evasion of cell death, and enhanced proliferation. Nitric oxide is produced in cancer stem cells through increased levels of the enzyme nitric oxide synthase 2 (NOS2); decreasing the level or activity of this enzyme reduces cancer stem cell growth. When drugs inhibiting the NOS2 enzyme were given to mice with gliomas, the growth of the tumors was delayed. Using the National Institutes of Health supported database of glioma specimen data, they also found that increased levels of this enzyme are associated with decreased survival of glioma patients. Targeting this pathway could therefore provide benefits for glioma patients.

Current therapies for cancer have many side effects, because they rely on the increased sensitivity of the cancer cells to drugs which are toxic to normal cells. It is therefore important to consider the potential side effects of any new proposed cancer treatment. The current study did compare the levels of the enzyme NOS2 and the effects of its inhibitors in cancer stem cells and normal neural stem cells. Normal neural stem cells have some similar properties as cancer stem cells from gliomas but cannot form tumors. Only cancer stem cells were found to depend on the enzyme for their growth. Drugs inhibiting the NOS2 enzyme were evaluated in patients for the treatment of other diseases and had minimal toxicity. The authors suggest that these drugs may therefore be useful for enhancing the effects of current therapies without adding a lot of side effects. NOS2 inhibitors may thereby pose a potential therapeutic breakthrough for this lethal disease.


'/>"/>

Contact: Dan Doron
dorond@ccf.org
216-312-0428
Lerner Research Institute
Source:Eurekalert

Related medicine news :

1. To combat deadly brain cancer, target the stem cells
2. Cellular origin of deadly brain cancer is identified
3. What causes brain cancer?
4. Research Sheds Light on Cause of Brain Deficits in HIV Patients
5. Intensive care nurses have doubts about method for establishing brain death
6. Lack of empathy following traumatic brain injury linked to reduced responsiveness to anger
7. Religion benefits traumatic brain injury victims, Wayne State University research finds
8. Advances in delivery of therapeutic genes to treat brain tumors
9. Study reveals possible brain damage in young adult binge-drinkers
10. Slow growth of childhood brain tumors linked to genetic process seen in skin moles
11. Poor Brain Sync a Possible Sign of Autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Petersburg, FL (PRWEB) , ... April 29, 2016 , ... ... look at products on the market. They recently reviewed the ZEN BOX , ... Typically there are two single essential oils (like lavender or frankincense) and one Zen ...
(Date:4/28/2016)... ... April 28, 2016 , ... Sanford Health’s work in ... group of researchers and leaders from Sanford Health were selected to participate in ... Cultural Impact ” and receive the 2016 Pontifical Key Innovation Award at the ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... is proud to partner with AquaShieldUSA, the country's oldest waterproof cast protector ... and medical supply stores, the largest selection of daily, night, weatherproof and waterproof ...
(Date:4/28/2016)... Austin, TX (PRWEB) , ... ... ... Data Interchange Standards Consortium (CDISC) announces today the open availability of a ... official platforms and catalogs for registering clinical trials. This innovative standard will ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... the Campaign for Tobacco-Free Kids, a leading force in the fight to reduce ... state and local policies that can help reduce tobacco use. The initiative brings ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... TOKYO , April 28, 2016 /PRNewswire/ ... Ahuja , George Phillips und ... wachsenden Unternehmens    ArisGlobal®, ein ... Life Sciences, gab heute bekannt, dass neue ... wachsenden Unternehmens gestoßen sind, die vielfältige Erfahrungen ...
(Date:4/28/2016)... YORK , April 28, 2016 ... online consumer insights on healthcare, announced today that it ... their report Cool Vendor in Life Sciences, 2016, ... April 15, 2016.  The report focuses on life-science- oriented ... gain insight from patients and doctors, confirm medication ingestion, ...
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life sciences, ... team to bring a wealth of insight to a growing business. ... knowledge. George Phillips joined ArisGlobal in the ...
Breaking Medicine Technology: